Raising the Bar for Patients with HR+/HER2- Early Breast Cancer

It is with great pleasure that I invite you to participate in a new ESMO webinar on management of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

This webinar is developed with the aim to provide an overview on risk assessment and rational application of adjuvant strategies in patients with early luminal HER2-negative breast cancer, on the value of CDK4/6 inhibitors in the adjuvant management of these patients, as well as to highlight ongoing research in this field.

We will begin with a lecture on clinicopathologic and molecular tools for assessing risk when managing patients with HR-positive, HER2-negative early breast cancer. This will be followed by updated data in terms of clinical results and implications for practice of the latest evidence from CDK4/6 inhibitors trials in the management of these patients. Finally, there will be multidisciplinary team presentation of two clinical cases that will highlight efficacy, safety, and patient communication aspects, followed by discussion with the audience.

The programme is designed to provide an overview of the current evidence, offer expert opinion exchange, interaction with audience and provide some important considerations regarding multidisciplinary assessment and management of patients with HR-positive, HER-negative early breast cancer in the personalised medicine era. I strongly encourage and invite you to register and join us all in this ESMO activity.

Prof. Dr. med. Sibylle Loibl

Chair and CEO, German Breast Group, Neu-Isenburg, Germany
Goethe University, Frankfurt, Germany
Bethanien Centre for Haematology and Oncology, Frankfurt, Germany